IRCT20201129049534N1已完成3 期
The effects of L-carnitine supplementation on inflammatory factors, oxidative stress and clinical outcomes in sepsis patients admitted to the intensive care unit (ICU): A double-blind randomized clinical controlled trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Diagnosis of sepsis based on blood culture and approval of an ICU specialist and anesthesiologist and infectious disease specialist
- •Gastrointestinal with normal function and intestinal nutrition criteria
- •Accept informed consent
排除标准
- •Patient or family dissatisfaction
- •Patients who are hospitalized in the ICU for less than 48 hours or do not have the possibility of intestinal feeding and patients who receive nutritional support with full intravenous feeding
- •Patients who do not have an indication for intestinal nutrition on the first day and are confirmed and predicted based on the diagnosis of the intensive care unit that they will not be able to receive intestinal nutrition in the future. (Nausea, persistent vomiting, ileus, intestinal obstruction, uncontrolled diarrhea (> 500 ml per day), high-output fistula (> 500 ml per day), intestinal inaccessibility, incomplete resuscitation and hemodynamic instability
- •Cancer patients undergoing chemotherapy and taking cisplatin
- •Patients taking anticonvulsants (phenobarbital and phenytoin)
- •Patients taking pivalic acid, valproic acid and Ifosfamide
- •Patients taking levetiracetam
- •Patients undergoing dialysis
- •Patients with hyperthyroidism and hypothyroidism
- •Severe and progressive septic shock
- •Patients who are expected to die within 2 days of admission to the ICU
- •Patients with BMI<18.5 kg/m2 admitted to the IC
研究者
相似试验
招募中
3 期
Effect of l-carnitine supplementation on inflammation, blood glucose and lipids in hemodialysis childreCondition 1: Chronic kidney disease, stage 5. Condition 2: dialysis complications. Condition 3: Dialysis-induced inflammation. Condition 4: Hyperlipidemia. Condition 5: hyperglycemia. Condition 6: carnitine deficiency. Condition 7: Disorder of fatty-acid metabolism.Chronic kidney disease, stage 5Kidney dialysis as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedureInfection and inflammatory reaction due to other internal prosthetic devices, implants and graftsHyperlipidemia, unspecifiedHyperglycemia, unspecifiedOther secondary carnitine deficiencyDisorder of fatty-acid metabolism, unspecifiedN18.5Y84.1T85.7E78.5R73.9E71.448E71.30IRCT20170202032367N2Tehran University of Medical Sciences30
尚未招募
2 期
The effect of intravenous L-carnitine supplementation during oxaliplatin based chemotherapy on blood- and urinary levels of carnitineCarnitine metabolisme, excretie, deficiëntie, interactie met chemotherapie (oxaliplatin)Deficiency/lack of/reduction of concentration of carnitine (an amino acid or half-vitamin) during/caused by treatment with chemotherapy (oxaliplatin)10013317NL-OMON48693Maxima Medisch Centrum10
招募中
3 期
Effect of L-carnitine in Ischemic StrokeIschemic stroke.Cerebral infarctionIRCT20221206056734N1Ahvaz University of Medical Sciences82
招募中
不适用
Effects of supplementation with L-carnitine in the heart of patients who will do coronary artery bypass graftCardiovascular disease, myocardial ischemia, heart failure.C14.280.647C14.280.434RBR-57hj7nniversidade Federal Fluminense
招募中
3 期
The Effect of L-Carnitine supplementation administration rout on the prognosis of patientsPatients admitted to the intensive care unit.Follow-up examination after unspecified treatment for other conditionsZ09.9IRCT20170903036041N4Iran University of Medical Sciences135